All the MRC funded studentships at IOPPN for 2025 entry listed here: kcl-mrcdtp.com/apply/projects/

Open Access: "The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity" researchgate.net/publication/10…

Just published: a state of the art review from Andrea Ulrichsen, part of her PhD work - "Do sleep variables predict mood in bipolar disorder: A systematic review". tl;dr: yes, but it's complex (and it matters how you measure them) sciencedirect.com/science/articl…

Quetiapine may pip lithium to the augmentation post in 'treatment resistant depression': results from the LQD study buff.ly/Y7jCajZ #LQDstudy #Quetiapine #Lithium #Depression #RCT

Published today in Lancet Psychiatry, after 7 years of hard labour... the first long-term head-to-head comparison of two augmentation treatments in treatment resistant depression. Clinical and cost-effectiveness of lithium versus quetiapine augmentat... sciencedirect.com/science/articl…

Summary of our recent LQD Study that found quetiapine to be more clinically effective and cost-effective in treatment resistant depression kcl.ac.uk/news/quetiapin… KCL CfAD Institute of Psychiatry, Psychology & Neuroscience

Quetiapine may pip lithium to the post for augmentation in ‘treatment resistant depression’: results from the LQD study nationalelfservice.net/mental-health/…

Excellent work from Laith Alexander 🏳️‍🌈 in our Centre for Affective Disorders KCL CfAD

Watch this interview with Dr Hamilton Morrin about neurotechnology treatments in psychiatry and neurology youtube.com/watch?v=gvpJQ_… To hear more, register for the King’s Health Partners and Maudsley Neurotechnology conference on 15th May here estore.kcl.ac.uk/conferences-an… #Neurotech

Glad to have been part of the PAX-D study, which confirms what we were seeing in clinic - pramipexole (a dopaminergic drug) can help many people with difficult to treat depression. Congrats to Michael Browning for successfully leading the trial and colleagues at KCL CfAD who took part

Great summary of the study here

Most studies on esketamine (and the UK licence) have been as add-on to antidepressants. This study suggests monotherapy may also be effective - although only short term data. As ever the challenge with (es)ketamine comes in the longer term.